Conditions: Leukemia, Myeloid, Chronic-Phase
Keywords: chronic myeloid leukemia in chronic phase residual plasma IM concentration adapted strategy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 68
Healthy volunteers: no

Brief summary:
The Imatinib Mesylate at a dose of 400 mg / day is the standard treatment for patients with CML-CP. Recent studies show that the quality of response rate (complete cytogenetic response and major molecular response rate) is dependent on the residual plasma Imatinib.

Detailed description:
The Imatinib Mesylate at a dose of 400 mg / day is the standard treatment for patients with CML-CP. Recent studies show that the quality of response rate (complete cytogenetic response and major molecular response rate) is dependent on the residual plasma Imatinib. This study aims to evaluate the effectiveness of a strategy for dose adjustment of Imatinib Mesylate based on the measurement of the residual plasma imatinib in patients treated for at least 2 years Imatinib 400 mg / d in complete cytogenetic response for at least 1 year.

Arms:
arm 1: Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po arm 2: Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po arm 3: Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po

Interventions: intervention 1: Imatinib Mesylate 600 MG Oral Tablet intervention 2: Imatinib Mesylate 400 MG Oral Tablet intervention 3: Imatinib Mesylate
Intervention descriptions: intervention 1: Imatinib Mesylate for CP CML intervention 2: Imatinib Mesylate for CP CML intervention 3: Imatinib Mesylate for CP CML

Protocol document: